It was found that the combination of RPS sorafenib increased the anti-cancer effect, overcoming the tolerance of sorafenib by protecting mitochondrial damage, inhibiting anaerobic glycolytic through PI3K/AKT/mTOR pathway (Yao et al., 2018). This evidence concerns the gene AKT1 and cancer.